Clinical Trial Update: A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update for the tyrosine kinase inhibitor orelabrutinib (ICP-022) in relapsed/refractory B-cell malignancies across Phase 1 and Phase 2 will ass…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Refractory B-cell Malignancies

Drugs mentioned

• Orelabrutinib (ICP-022) (orelabutinib)

Snippet

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. | Conditions: Part 1：r/r B-cell Malignancies, Part 2：B-cell Malignancies | Phase 1, Phase 2 | Status: UNKNOWN